Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells

Journal of Hypertension

Volumn 20, Issue 9, 2002, Pages 1807-1814

  Tahara, Atsuo ^a   Tsukada, Junko ^a   Tomura, Yuichi ^a   Kusayama, Toshiyuki ^a   Wada, Koh Ichi ^a   Ishii, Noe ^a   Yatsu, Takeyuki ^a   Uchida, Wataru ^a   Taniguchi, Nobuaki ^a   Tanaka, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Arginine vasopressin; Hyperplasia; Hypertrophy; Mitogen activated protein kinase; V1A receptor; Vascular smooth muscle cells; YM471

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 4' [4,4 DIFLUORO 5 [2 (4 DIMETHYLAMINOPIPERIDINO) 2 OXOETHYLIDENE] 2,3,4,5 TETRAHYDRO 1H 1 BENZOAZEPINE 1 CARBONYL] 2 PHENYLBENZANILIDE; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; CALCIUM ION; DESMOPRESSIN; MITOGEN ACTIVATED PROTEIN KINASE; MOZAVAPTAN; OXYTOCIN; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; YM 471;

ARTICLE; CELL HYPERPLASIA; CONTROLLED STUDY; ENZYME ACTIVITY; HORMONAL REGULATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

EID: 18544378588     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200209000-00026     Document Type: Article

References (37)

1. Arginine vasopressin-induced hypertrophy of cultured rat aortic smooth muscle cells
2. 1a antagonist, on human vascular smooth muscle cells
3. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis
4. The changes in plasma arginine-vasopressin in patients with essential hypertension and the correlation with patient's condition
5. 1a vasopressin receptor
6. 1a arginine vasopressin receptor
7. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C
8. Activation of MAP kinases by calcium-dependent and calcium-independent pathways. Stimulation by thapsigargin and epidermal growth factor
9. Phosphorylation of c-jun mediated by MAP kinases
10. Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation. Characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase
11. Direct evidence for tyrosine and threonine phosphorylation and activation of mitogen-activated protein kinase by vasopressin in cultured rat vascular smooth muscle cells
12. Pharmacology and clinical perspectives of vasopressin antagonists
13. Design and uses of selective agonistic and antagonistic analogs of the neuropeptides oxytocin and vasopressin
14. Discovery, development, and some uses of vasopressin and oxytocin antagonists
15. 2 receptor antagonist
16. Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues
17. 50) of an enzymatic reaction
18. 2+ indicators with greatly improved fluorescence properties
19. 3H]thymidine incorporation assay
20. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells
21. 2 receptor antagonist, in vitro and in vivo
22. The role of vasopressin in hypertension
23. Vasopressin and hypertension in man
24. Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors
25. 1A receptor antagonism
26. The role of vasopressin in essential hypertension
27. Replication of arterial smooth muscle cells in hypertension and atherosclerosis
28. Endothelium and growth factors in vascular remodeling of hypertension
29. Endothelin-1 promotes neointima formation after balloon angioplasty in the rat
30. Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries
31. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
32. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF
33. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma
34. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells
35. ANG II- or AVP-induced increases in protein synthesis are not dependent on autocrine secretion of PDGF-AA
36. Endothelin production in cultured vascular smooth muscle cells - Modulation by the atrial, brain, and C-type natriuretic peptide system
37. Mechanical strain and collagen potentiate mitogenic activity of angiotensin II in rat vascular smooth muscle cells